Sw480

Two human colon cancer cell lines (HCT-116, SW-480) were purchased from Shanghai Zhong Qiao Xin Zhou Biotechnology Co., Ltd. (Shanghai, China). Cells were maintained in DMEM medium (SH30084.03, Hyclone, USA) containing 10% fetal bovine serum (11,885,084, Gibco, USA) in a humidified atmosphere with 5% CO₂ at 37 °C.

CC cells, including SW480, Colo-205, SW620, HCT15, DLD-1, HCT116, Caco-2, RKO and LOVO were bought from Shanghai Zhong Qiao Xin Zhou Biotechnology. SW480 and SW620 were cultured in a complete DMEM medium supplemented with 10% FBS (Gibco Grand Island, NY, USA). Colo-205, HCT15 and DLD-1 cells in a complete RPMI-1640 medium supplemented with 10% FBS. Caco-2 and RKO cells in a complete EMEM medium supplemented with 10% FBS. HCT116 cells in a complete Mccoy’s 5A medium supplemented with 10% FBS. LOVO cells in a complete F-12K medium supplemented with 10% FBS. All the experimental procedures described below were repeated thrice unless described otherwise.

Human colon cancer cell lines HCT116 (non-metastatic colon cancer cells, ZQ0125), SW480 (moderately metastatic colon cancer cells, ZQ0063), Lovo (highly metastatic colon cancer cells, ZQ0058), and the mouse colon adenocarcinoma cell line MC38 (ZQ0933) were purchased from Shanghai Zhong Qiao Xin Zhou Biotechnology Co. Ltd (Shanghai, China). HCT116, SW480, and MC38 cells were cultured in DMEM (KGM12800-500, Keygen Biotech, Nanjing, China) with 10% fetal bovine serum (FBS, 164210-50, Procell, Wuhan, China). Lovo cells were cultured in Ham’s F-12K medium (G4560-500ML, Servicebio, Wuhan, China) supplemented with 10% FBS. All cells were maintained in a 5% CO₂-containing incubator (Thermo Fisher Scientific, Waltham, MA, USA) at 37 °C.

The human colorectal cancer (CRC) cell lines of SW480, SW620 and HCT116 were obtained from Shanghai Zhong Qiao Xin Zhou Biotechnology Co., Ltd. and cultured in DMEM medium (Gibco, USA) supplemented with 10% fetal bovine serum (BI, USA) at 37 °C in 5%CO₂. In order to evaluate the influence of NF-κB pathway on the migration, invasion and EMT of CRC cells, cells were treated with NF-κB pathway inhibitor BAY 11–7082 (10 μM, medchemexpress, USA) for 48 h before following experiments.